Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
Authors: Ricardo S. Kuchenbecker, Marcelo Martins Reis, Guilherme Barreiro
Journal: Annals of Internal Medicine (2011)

Letters20 September 2011Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1Ricardo S. Kuchenbecker, PhD, Marcelo Martins Reis, and Guilherme BarreiroRicardo S. Kuchenbecker, PhDFrom Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, CEP 90035-903 Porto Alegre, Brazil.Search for more papers by this author, Marcelo Martins ReisFrom Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, CEP 90035-903 Porto Alegre, Brazil.Search for more papers by this author, and Guilherme BarreiroFrom Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, CEP 90035-903 Porto Alegre, Brazil.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-6-201109200-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:On behalf of the AIDS Clinical Trials Group (ACTG) Study A5202 Team, Daar and colleagues (1) reported the results of an open-label, randomized equivalence trial to compare atazanavir plus ritonavir or efavirenz with placebo-controlled abacavir–lamivudine or tenofovir disoproxil fumarate–emtricitabine. We believe that the A5202 study has some biases that may substantially compromise its internal validity.The open-label design of the study has probably influenced adjudication of the primary outcomes, such as time to the occurrence of adverse effects or tolerability, thus making the study prone to performance bias. It was able to declare equivalence among the compared ...References1. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al; AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445-56. [PMID: 21320923] LinkGoogle Scholar2. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106. [PMID: 18480202] CrossrefMedlineGoogle Scholar3. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145:62-9. [PMID: 16818930] LinkGoogle Scholar4. Parienti JJ, Verdon R, Massari V. Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance. BMC Med Res Methodol. 2006;6:46. [PMID: 16987409] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, CEP 90035-903 Porto Alegre, Brazil.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoGood Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials Sanjay Kaul and George A. Diamond Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Eric S. Daar , Camlin Tierney , Margaret A. Fischl , Paul E. Sax , Katie Mollan , Chakra Budhathoki , Catherine Godfrey , Nasreen C. Jahed , Laurie Myers , David Katzenstein , Awny Farajallah , James F. Rooney , Keith A. Pappa , William C. Woodward , Kristine Patterson , Hector Bolivar , Constance A. Benson , Ann C. Collier , and Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Eric S. Daar , Ann A. Collier , and Camlin Tierney Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Philippe Flandre Metrics 20 September 2011Volume 155, Issue 6Page: 402-403KeywordsClinical trial reportingConflicts of interestHIV-1NucleosidesProtease inhibitorsReverse transcriptase inhibitorsSafetySafety studiesViral load ePublished: 20 September 2011 Issue Published: 20 September 2011 CopyrightCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...